In this special podcast recorded from the 2024 Australasian Melanoma Conference, we hear from our international keynote speakers, Prof Susan Swetter and Prof Olivier Michelin, about what excites them in the field of melanoma research.

Interviewed by AMC2024 Co-Chairs, Prof Georgina Long AO and Prof Richard Scolyer AO, our guests provide their multidisciplinary perspectives and highlight the importance of working together to make an impact in melanoma prevention and patient care.

Dermatologist Prof Swetter discusses the evolving role of AI in dermatology and the clinical diagnosis of melanoma, and highlights the opportunity for improved prevention strategies in the US to reduce the incidence of melanoma.

Prof Michelin explores how we’re tackling advanced melanoma, in particular to maximize our current treatment tools and manage drug toxicities. He also discusses expanding access to neoadjuvant therapies and the potential of TIL therapies, alongside AI advancements in histopathological diagnosis to personalise treatment approaches.

This podcast is suitable for multidisciplinary healthcare professionals and researchers.

SPEAKERS

• Prof Georgina Long AO - Co-Medical Director, Melanoma Institute Australia | Chair, Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia and Royal North Shore Hospital, The University of Sydney |2024 Joint Australian of the Year

• Prof Richard Scolyer AO - Co-Medical Director, Melanoma Institute Australia | Pathologist, Melanoma Institute Australia, Senior Staff Specialist, Royal Prince Alfred Hospital | Clinical Professor, The University of Sydney |2024 Joint Australian of the Year

• Prof Susan Swetter - Professor of Dermatology, Co-Director of the Pigmented Lesion/Melanoma and Cutaneous Oncology Programs, Stanford University Medical Center and Cancer Institute | Chair, National Comprehensive Cancer Network Melanoma Panel

• Prof Olivier Michelin - Chair, Department of Oncology and the Precision Oncology Service, Geneva University Hospital | Co-Director, Swiss Cancer Centre Léman| Vice-Coordinator, Translational Research Centre in Onco-Hematology

Please note that this podcast was accurate at the time of recording (October 2024) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.